4DMT Highlights Recent Clinical Pipeline Progress, Near-Term Milestones and Organizational Updates
Poised for multiple meaningful catalysts in 2024 driven by strong clinical progress across large market programs in wet age-related macular...
Year: 2024
First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer
Media Release SYDNEY, AUSTRALIA, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”),...
Alimera Completes Recruitment for the Synchronicity Study
Study with YUTIQ® has Surpassed Goal of 100 Patients EnrolledATLANTA, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq:...
BiomX Receives Orphan Drug Designation from the U.S. Food and Drug Administration for BX004 for the Treatment of Chronic Pulmonary Infection Caused by Pseudomonas aeruginosa in Patients with Cystic Fibrosis
CAMBRIDGE, Mass. and NESS ZIONA, Israel, Jan. 04, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX”), a clinical-stage company advancing...
ProPhase poised to ramp up growth at Pharmaloz and Nebula Genomics in 2024
Company also plans to commercialize its BE-Smart Esophageal Cancer Test in 2024Company announces the hiring of long-time industry veteran Jed...
Reviva Provides Corporate and Program Updates and Highlights Key Upcoming Milestones
– Schizophrenia late-stage clinical program advances with positive topline Phase 3 data, successful ongoing enrollment in open label extension (OLE)...
OncoC4 to Present at the 42nd Annual J.P. Morgan Healthcare Conference
ROCKVILLE, Md., Jan. 04, 2024 (GLOBE NEWSWIRE) -- OncoC4, Inc. (“OncoC4”), a late-stage biopharmaceutical company developing novel medicines for cancer,...
Korro to Present at the 42nd Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that Chief Executive Officer...
Livestock Impact, Inc., Subsidiary of BioAdaptives, Inc., Launches Innovative Food Lab for Development of Treats and Supplement Powder for Human, Equine, and Canine Products
LAS VEGAS, NV, Jan. 04, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – BioAdaptives Inc. (OTC: BDPT), a leading manufacturer and...
Black Diamond Therapeutics Announces Corporate Update and Expected 2024 Milestones
FDA feedback on BDTX-1535 enables initiation of Phase 2 cohort in first-line treatment of non-classical EGFR mutant NSCLC Fast Track...
Solid Biosciences to Participate at 42nd Annual J.P. Morgan Healthcare Conference
CHARLESTOWN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines...
ReWalk Robotics CEO Issues Year-End 2023 Open Letter to Shareholders and Provides 2024 Commercial and Operational Priorities
MARLBOROUGH, Mass. and BERLIN and YOKNEAM ILLIT, Israel, Jan. 04, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk”...
Cocrystal Pharma Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investigational Candidates
BOTHELL, Wash., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) provides an update...
Quanta Announces IND Clearance by U.S. FDA for QTX3034, G12D-Preferring Multi-KRAS Inhibitor, and Other Pipeline Updates
– First-in-human clinical trial evaluating QTX3034 as monotherapy and combination in patients with KRASG12D-mutated advanced solid tumors to begin in...
Third Harmonic Bio Appoints Christopher Murphy as Chief Financial and Business Officer and Provides Business Update
Chris brings extensive enterprise-level leadership experience in business development, commercial operations, and corporate strategy IND-enabling toxicology studies of THB335 nearing...
IN8bio Highlights Recent Company Accomplishments and Outlines 2024 Pipeline Goals
Presented positive data showing continued durable complete remissions (CR) achieved in 100% of evaluable leukemia patients in Phase 1 investigator-sponsored...
MedBright AI Appoints Trevor Vieweg as Chief Executive Officer
VANCOUVER, British Columbia, Jan. 04, 2024 (GLOBE NEWSWIRE) -- MedBright AI Investments Inc. (the “Company” or “MedBright AI”) (CSE:MBAI, OTCQB:MBAIF,...
Claris Bio Emerges From Stealth With a New Investor and Prepares for Next Development Stage With Late-Stage Data Expected in 1H24
Company Funded by Novo Holdings A/S, RA Capital, Mass General Brigham Ventures, Expands Syndicate With Financing from Janus Henderson InvestorsLead...
Recursion Adds New Chemical Entity Targeting Fibrotic Diseases to Late Discovery Pipeline
Potential First-in-Class Novel Molecule with Novel Target In-Licensed from Collaboration with BayerSALT LAKE CITY, Jan. 04, 2024 (GLOBE NEWSWIRE) --...
ITM Announces Operational Readiness for NOVA Facility, the World’s Largest Lutetium-177 Production Site
Receipt of Radioactive Material Handling License (RAM License) for production of n.c.a. Lutetium-177Progress demonstrates company’s ability to rapidly increase GMP...